

Askina® Calgitrol® Paste

Versatility at your fingertips




Did you know?

Infection is a common problem in chronic wounds – and a big challenge to wound care professionals. These wounds also cause significant costs in the healthcare system.^{1,2,3}



1–2%

of the population in developed countries will experience a chronic wound sometime in their lives.⁴




+50%

of chronic wounds are estimated to be infected.^{5,6}

Askina® Calgitrol® Paste


Ionic Silver Alginate Dressing in Soft Paste Form

Askina® Calgitrol® Paste is a state-of-the-art wound dressing designed to treat chronic wounds which are infected or at high risk of infection. Its paste form simplifies wound treatment by eliminating the need to cut dressings to fit the wound or find dressings in the right size.



Mode of Action

Askina® Calgitrol® Paste's water content makes silver ions immediately available and provides a sustained release of ionic silver to the wound bed.⁸



Clinical Case

A 69-year-old man with type 2 diabetes developed an ulcer on the lateral aspect of the fifth metatarsal of the left foot. The therapy applied was Askina® Calgitrol® Paste, with Prontosan® Wound Irrigation Solution used for cleansing. After 4 weeks the wound area decreased by 97.67%.¹²

Day 1

Wound post-debridement with Askina® Calgitrol® Paste applied



Day 7

Wound-healing progress



Day 14

Continued wound-healing progress



Wounds may often go unseen, but their impact is real.
Askina® Calgitrol® Paste not only treats wounds but
also simplifies professional care.



Ordering Information

Size	Box quantity	B. Braun article code
15 g	5	7211598
15 g	10	7211599

See more information



References:

1. Phillips CJ, Humphreys I, Fletcher J, Harding K, Chamberlain G, Macey S. Estimating the costs associated with the management of patients with chronic wounds using linked routine data. *Int Wound J*. 2016 Dec;13(6):1193-1197. doi: 10.1111/iwj.12443. Epub 2015 Mar 26. PMID: 25818405; PMCID: PMC7949824.
2. Purwins S, Herberger K, Debus ES, Rustenbach SJ, Pelzer P, Rabe E, Schäfer E, Stadler R, Augustin M. Cost-of-illness of chronic leg ulcers in Germany. *Int Wound J*. 2010 Apr;7(2):97-102. doi: 10.1111/j.1742-481X.2010.00660.x. PMID: 20529149; PMCID: PMC7951196.
3. Frykberg RG, Banks J. Challenges in the Treatment of Chronic Wounds. *Adv Wound Care (New Rochelle)*. 2015 Sep 1;4(9):560-582. doi: 10.1089/wound.2015.0635. PMID: 26339534; PMCID: PMC4528992.
4. Falanga V, Isseroff RR, Soulika AM, Romanelli M, Margolis D, Kapp S, Granick M, Harding K. Chronic wounds. *Nat Rev Dis Primers*. 2022 Jul 21;8(1):50. doi: 10.1038/s41572-022-00377-3. PMID: 35864102; PMCID: PMC10352385.
5. Reitan RL, McBroom RM, Gilder RE. The Risk of Infection and Indication of Systemic Antibiotics in Chronic Wounds. *Wounds*. 2020 Jul;32(7):186-194. PMID: 33166266.
6. Schollemann F, Kunczik J, Dohmeier H, Pereira CB, Follmann A, Czaplik M. Infection Probability Index: Implementation of an Automated Chronic Wound Infection Marker. *J Clin Med*. 2021 Dec 29;11(1):169. doi: 10.3390/jcm11010169. PMID: 35011910; PMCID: PMC8745914.
7. Chadwick P. Using Askina® Calgitrol® Paste in the treatment of diabetic foot infection: case studies. London: Wounds International, 2013.
8. Nicodeme M, Cheron M, Kriegel I, Jaimes H, Fromantin I. A silver alginate paste dressing in the management of non-malignant wounds with signs of infection in oncology patients: an observational prospective case series. *Wounds International* 2021; 12 (3): 70-7.
9. Zone of Inhibition Testing of Askina Calgitrol Paste (internal report ref HOSP 247A).
10. In Vitro Kill Curve Study (internal report ref. HOSP 254).
11. Naude L. The use of Prontosan® in combination with Askina® Calgitrol®: an independent case series. *Wounds International* 2018; 9 (1): 44-8.
12. Lázaro Martínez, JL (2024): Retrospective case series: Prontosan® Solution and Askina® Calgitrol® Paste in the treatment of diabetic foot ulcers. *Wounds International*, London, UK.